In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 37 for your search:
Cancer Type/Condition:  Brain tumor, child: Ependymoma/Ependymal tumors
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ACNS0831, NCI-2011-02029, COG-ACNS0831, CDR0000668560, U10CA098543, NCT01096368

2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 2013-062, NCI-2013-02001, P30CA022453, NCT01987596

3.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 32
Sponsor: Pharmaceutical / Industry
Protocol IDs: CNS 0201, NCT00179907

4.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ADVL0912, COG-ADVL0912, CDR0000647587, NCT00939770

5.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: DFI12860, 2010-019340-40, MOZ15609, NCT01288573

6.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 10-096, NCT01294670

7.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED12689, U1111-1128-5704, NCT01751308

8.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965

9.

Phase: Phase II
Type: Treatment
Status: Active
Age: Children
Sponsor: Other
Protocol IDs: 2005-12-009, NCT00798811

10.

Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 20 years
Sponsor: Other
Protocol IDs: CSET 2008/1378, NCT00918320

11.

Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458

12.

Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476

13.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 21
Sponsor: Other
Protocol IDs: CMH 09C4, NCT01088035

14.

Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 10-206, NCT01288235

15.

Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SNUCH-SCT-1102, NCT01342237

16.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO25041, 2010-022189-28, ITCC-019, HGG-01, NCT01390948

17.

Phase: Phase II
Type: Treatment
Status: Active
Age: 6 to 18
Sponsor: Other
Protocol IDs: HSJD-GLIOMAS-IC, NCT01574092

18.

Phase: Phase II
Type: Treatment
Status: Active
Age: 12 months to 21 years
Sponsor: NCI, Other
Protocol IDs: PBTC-036, NCI-2013-00482, U01CA081457, NCT01836549

19.

Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI, Other
Protocol IDs: CDR0000257582, UIHC-200008086, NCI-V02-1710, 200008086, NCT00049023

20.

Phase: Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: RADBEV, NCT00756340

21.

Phase: Phase I
Type: Treatment
Status: Approved-not yet active
Age: 3 to 21
Sponsor: Other
Protocol IDs: CNS 1100, NCT00836628

22.

Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 22
Sponsor: Pharmaceutical / Industry
Protocol IDs: 07-098, NCT00634231

23.

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 months to 23 years
Sponsor: Other
Protocol IDs: ACH-CNS-001, NCT00876993

24.

Phase: Phase I
Type: Treatment
Status: Active
Age: Under 18
Sponsor: NINDS
Protocol IDs: 090117, 09-N-0117, NCT00880061

25.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 19 at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2011-02539, 10-C-0219, CDR0000687467, NCI-10-C-0219, 8449, NCT01226940
1   
New Search